Literature DB >> 12115641

Ly-6A is critical for the function of double negative regulatory T cells.

Zhu-Xu Zhang1, William L Stanford, Li Zhang.   

Abstract

We have recently demonstrated that CD3+CD4-CD8- double negative (DN) T cells can down-regulate allogeneic immune responses both in vitro and in vivo by killing activated syngeneic CD8+ T cells. The goal of this study was to identify molecules that are crucial for DN T cell-mediated suppression. We demonstrate that Ly-6A (Sca-1) is highly expressed on DN T cells. Incubation with IL-10 significantly reduced Ly-6A expression and the function of DN T cells. DN T cell-mediated killing was significantly reduced when Ly-6A was blocked.Ly-6A-deficient mice showed an accelerated allograft rejection when compared to wild-type controls. Furthermore we demonstrate that pretransplantation donor lymphocyte infusion (DLI) led to activation and proliferation of recipient DN T cells and prolongation of bm1-->B6 skin allograft survival. However, when the recipients were deficient in Ly-6A, the beneficial effect of DLI on allograft survival was abolished. Moreover, deficiency in Ly-6A did not affect the activation and proliferation of DN T cells. Rather, it impaired the ability of DN T cells to kill activated anti-donor CD8+ T cells. Taken together, our data indicate that Ly-6A plays a crucial role in DN T cell-mediated regulation in vitro and in vivo, perhaps by enhancing DN-CD8+ T cell signaling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115641     DOI: 10.1002/1521-4141(200206)32:6<1584::AID-IMMU1584>3.0.CO;2-2

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

Review 1.  Double-negative regulatory T cells: non-conventional regulators.

Authors:  Christopher W Thomson; Boris P-L Lee; Li Zhang
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Markers of nonselective and specific NK cell activation.

Authors:  Leslie A Fogel; Michel M Sun; Theresa L Geurs; Leonidas N Carayannopoulos; Anthony R French
Journal:  J Immunol       Date:  2013-05-08       Impact factor: 5.422

3.  Infusion of ex-vivo expanded human TCR-αβ+ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease.

Authors:  P Achita; D Dervovic; D Ly; J B Lee; T Haug; B Joe; N Hirano; L Zhang
Journal:  Clin Exp Immunol       Date:  2018-07-31       Impact factor: 4.330

4.  Pretransplant infusion of donor B cells enhances donor-specific skin allograft survival.

Authors:  Julia Gao; Megan S Ford McIntyre; Cheryl A D'Souza; Li Zhang
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

5.  Dissecting the cellular landscape and transcriptome network in viral myocarditis by single-cell RNA sequencing.

Authors:  Ninaad Lasrado; Nicholas Borcherding; Rajkumar Arumugam; Timothy K Starr; Jay Reddy
Journal:  iScience       Date:  2022-02-02

Review 6.  CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer.

Authors:  Zhiheng Wu; Yu Zheng; Jin Sheng; Yicheng Han; Yanyan Yang; Hongming Pan; Junlin Yao
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

Review 7.  Application of double-negative T cells in haematological malignancies: recent progress and future directions.

Authors:  Xingchi Chen; Dongyao Wang; Xiaoyu Zhu
Journal:  Biomark Res       Date:  2022-03-14

8.  Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.

Authors:  Erin E Hillhouse; Jean-Sébastien Delisle; Sylvie Lesage
Journal:  Front Immunol       Date:  2013-01-24       Impact factor: 7.561

9.  The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo.

Authors:  Megan S Ford; Kevin J Young; Zhuxu Zhang; Pamela S Ohashi; Li Zhang
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

10.  Identification of CD3+CD4-CD8- T cells as potential regulatory cells in an experimental murine model of graft-versus-host skin disease (GVHD).

Authors:  Fumi Miyagawa; Naoko Okiyama; Vadim Villarroel; Stephen I Katz
Journal:  J Invest Dermatol       Date:  2013-05-06       Impact factor: 8.551

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.